EXT1 and EXT2, from exostosin-1 and −2, were originally described as tumor suppressors following the observation that mutations in the corresponding genes were found in patients suffering from hereditary multiple exostoses, a disorder characterized by cartilaginous and bone tumors18–20. This evidence concerns the gene EXT1 and neoplasm.